ScholarLens Back to search
1989•Orthopedics & TraumatologyOpen access

Clinical study of Bucillamine on rheumatoid arthritis patients.

Minoru Ikeda, Koichi Iwashige, Koji Kuroda, Akio Nakamura, Eisuke Shono, N. Takagishi

Open full text 0 citations

Abstract

We treated 20 patients diagnosed under the new ARA criteria for rheumatoid arthritis (RA) with Bucillamine 100mg-300mg/day.There was an improvement rate of 85%. Effectiveness was especially marked in early RA patients but it was seen also progressed RA patients, and it was seen in about eight weeks after administration.The drug was effective in patients who had changed over from injectable gold salts, Dpenicillamine and Auranofin. It's side effects were seen in 30% of the patients, but severe ones were not seen in our cases. Among remission inducing agents, this drug was one that could be administered early.

Open-access reader

About this research paper

What this paper is about

We treated 20 patients diagnosed under the new ARA criteria for rheumatoid arthritis (RA) with Bucillamine 100mg-300mg/day.There was an improvement rate of 85%. Effectiveness was especially marked in early RA patients but it was seen also progressed RA patients, and it was seen in about eight weeks after administration.The drug was effective in patients who had changed over from injectable gold salts, Dpenicillamine and Auranofin. It's side effects were seen in 30% of the patients, but severe ones were not seen in our cases. Among remission inducing agents, this drug was one that could be administered early.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

We treated 20 patients diagnosed under the new ARA criteria for rheumatoid arthritis (RA) with Bucillamine 100mg-300mg/day.There was an improvement rate of 85%. Effectiveness was especially marked in early RA patients but it was seen also progressed RA patients, and it was seen in about eight weeks after administration.The drug was effective in patients who had changed over from injectable gold salts, Dpenicillamine and Auranofin. It's side effects were seen in 30% of the patients, but severe ones were not seen in our cases. Among remission inducing agents, this drug was one that could be administered early.

Key concepts: Auranofin, Medicine, Rheumatoid arthritis, Drug, Internal medicine, Gastroenterology, Surgery, Pharmacology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Clinical study of Bucillamine on rheumatoid arthritis patients. — Research Paper | ScholarLens